scholarly journals Adjustable Algorithmic Tool for Assessing the Effectiveness of Maternal Respiratory Syncytial Virus (RSV) Vaccination on Infant Mortality in Developing Countries

2021 ◽  
Vol 2021 ◽  
pp. 1-7
Author(s):  
Rachel Cevigney ◽  
Christopher Leary ◽  
Bernard Gonik
Keyword(s):  
Developing Countries ◽  
Infant Mortality ◽  
Case Fatality ◽  
The United States ◽  
Mortality Rates ◽  
Incidence Rates ◽  
Acute Lower Respiratory Infection ◽  
Maternal Child Health ◽  
Incidence And Mortality ◽  
Country Specific

Acute lower respiratory infection (ALRI) due to RSV is a common cause of global infant mortality, with most cases occurring in developing countries. Using data aggregated from priority countries as designated by the United States Agency for International Development’s (USAID) Maternal Child Health and Nutrition (MCHN) program, we created an adjustable algorithmic tool for visualizing the effectiveness of candidate maternal RSV vaccination on infant mortality. Country-specific estimates for disease burden and case fatality rates were computed based on established data. Country-specific RSV-ALRI incidence rates for infants 0-5 months were scaled based on the reported incidence rates for children 0-59 months. Using in-hospital mortality rates and predetermined “inflation factor,” we estimated the mortality of infants aged 0-5 months. Given implementation of a candidate maternal vaccination program, estimated reduction in infant RSV-ALRI incidence and mortality rates were calculated. User input is used to determine the coverage of the program and the efficacy of the vaccine. Using the generated algorithm, the overall reduction in infant mortality varied considerably depending on vaccine efficacy and distribution. Given a potential efficacy of 70% and a maternal distribution rate of 50% in every USAID MCHN priority country, annual RSV-ALRI-related infant mortality is estimated to be reduced by 14,862 cases. The absolute country-specific reduction is dependent on the number of live births; countries with the highest birth rates had the greatest impact on annual mortality reduction. The adjustable algorithm provides a standardized analytical tool in the evaluation of candidate maternal RSV vaccines. Ultimately, it can be used to guide public health initiatives, research funding, and policy implementation concerning the effectiveness of potential maternal RSV vaccination on reducing infant mortality.

Solitary Plasmacytoma Incidence, Mortality, and Survival Trends in the United States

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 5629-5629
Author(s):  
Anirudh Bikmal ◽  
Lakshmi Radhakrishnan ◽  
Ajay K. Nooka
Keyword(s):  
Regression Analysis ◽  
Black Males ◽  
Survival Rates ◽  
The United States ◽  
Mortality Rates ◽  
Incidence Rates ◽  
Study Cohort ◽  
Solitary Plasmacytoma ◽  
Incidence And Mortality ◽  
Adjusted Incidence

Abstract Background: The trends of incidence of solitary bone plasmacytoma (SBP) varied over time due to the changing definitions and the absence of clarity of the criteria. Prior studies have attempted to identify factors such as older age, gender, race as prognostic factors that influence survival of patients with SBP, but with changing paradigm of myeloma treatments, there is limited literature regarding the incidence, mortality and survival trends of SBP. Methods: We used the SEER registry from 1973-2009 to evaluate the incidence, mortality and survival trends in patients with SBP. The results were reported as crude incidence, mortality and survival rates. Two-sample t-tests, ANOVA as well regression analysis were used to examine correlation. Statistics were computed using the National Cancer Institute SEER*Stat software, version 8.2.0. and SAS software, version 9.4 (SAS Institute Inc, Cary, NC). Using the ICD-O-3 and morphologic codes of 9731/3 to identify cases, the final study cohort consisted of 2,734 cases. Trends were evaluated by the eras of diagnosis: 1973-1980, 1981-1985, 1986-1990, 1991-1995, 1996-2000, 2001-2005, and 2006-2009. Age-adjusted incidence rates (IR), standard mortality rates (SMR), survival rate (SR) were expressed as new cases per 100,000 person-years, and age-adjusted to the 2000 US standard population. Results: The median age of diagnosis of SBP among blacks is 61 years (range, 21-91) compared to others: 60 years (range, 28-88) and whites: 66 years (20-97). The age adjusted incidence rates for black males is: 0.3 (95%CI 0.2, 0.3) followed by black females 0.2 (95%CI 0.1, 0.2) white males 0.2 (95%CI 0.2, 0.2) white females 0.1 (95%CI 0.1, 0.1). The trends in incidence and mortality rates are illustrated in table 1 with highest IR noted for black males during the era 2006-2009. The 5-year survival rates for both males (figure 1) and females (figure 2) seem to be trending down over the eras examined. Regression analysis suggests males and other race have increased odds of survival (HR = 0.829, p=0.0078; HR = 0.54 and p=0.0038, respectively). Conclusions: Similar to myeloma, black patients tend to be diagnosed with SBP younger and have increased incidence. The incidence rates seem to be increasing, highest among blacks males, more likely from increased awareness and diagnosis. The mortality and survival patterns are comparable to whites. Interestingly, while the 5-year survival for myeloma among all racial groups is improving this analysis shows a decreasing trend for SBP. This observation is more likely from including myeloma patients under the diagnosis of SBP over the period of study. Recently, the International Myeloma Working Group (IMWG) clarified the definition of SBP which will help in accurate diagnosis and ultimately can help in accurate representation of the survival trends. Table 1. Incidence and Mortality Rates across Study Eras (SEER-9), 1973-2009 Years White (IR) White (MR) Black (IR) Black (MR) Other (IR) Other (MR) Male 1973-1980 0 0 0 (0, 0.1) 0 (0, 0.1) 0 (0, 0.2) 0 (0, 0.1) 1981-1985 0 0 0 (0, 0.2) 0 (0, 0.1) 0 (0, 0.2) 0 (0, 0.1) 1986-1990 0.1 (0.1, 0.2) 0.1 (0, 0.1) 0.1 (0, 0.3) 0.1 (0, 0.2) 0.3 (0.1, 0.5) 0 (0, 0.2) 1991-1995 0.2 (0.1, 0.2) 0.1 (0.1, 0.2) 0.2 (0.1, 0.4) 0 (0, 0.1) 0.1 (0, 0.3) 0.1 (0, 0.2) 1996-2000 0.2 (0.2, 0.3) 0.1 (0.1, 0.1) 0.3 (0.1, 0.5) 0.2 (0.1, 0.4) 0.2 (0.1, 0.4) 0.2 (0, 0.4) 2001-2005 0.4 (0.4, 0.5) 0.2 (0.2, 0.3) 0.5 (0.3, 0.7) 0.3 (0.1, 0.6) 0.2 (0, 0.2) 0 (0, 0.2) 2006-2009 0.4 (0.4, 0.5) 0.2 (0.2, 0.3) 0.7 (0.4, 1) 0.3 (0.1, 0.5) 0.1 (0, 0.2) 0.1 (0, 0.2) Female 1973-1980 0 0 0 (0, 0.1) 0 (0, 0.1) 0 (0, 0.1) 0 (0, 0.1) 1981-1985 0 0 0 (0, 0.1) 0 (0, 0.1) 0 (0, 0.1) 0 (0, 0.1) 1986-1990 0.1 (0, 0.1) 0 (0, 0.1) 0.1 (0, 0.2) 0 (0, 0.1) 0 (0, 0.2) 0 (0, 0.2) 1991-1995 0.1 (0.1, 0.1) 0 (0, 0.1) 0.2 (0.1, 0.3) 0.1 (0, 0.2) 0 (0, 0.1) 0 (0, 0.1) 1996-2000 0.1 (0.1, 0.1) 0.1 (0.1, 0.1) 0.1 (0, 0.2) 0.1 (0, 0.2) 0.1 (0.2) 0 (0, 0.1) 2001-2005 0.2 (0.2, 0.2) 0.1 (0.1, 0.2) 0.3 (0.2, 0.4) 0.1 (0, 0.2) 0.1 (0, 0.2) 0 (0, 0.1) 2006-2009 0.2 (0.2, 0.3) 0.1 (0.1, 0.2) 0.3 (0.2, 0.5) 0.2 (0.1, 0.3) 0.1 (0, 0.2) 0 (0, 0.1) Figure 1. 5-year Survival Rates in males (SEER-9), 1973-2012 Figure 1. 5-year Survival Rates in males (SEER-9), 1973-2012 Figure 2. 5-year Survival Rates in females (SEER-9), 1973-2012 Figure 2. 5-year Survival Rates in females (SEER-9), 1973-2012 Disclosures Nooka: Spectrum Pharmaceuticals: Consultancy; Onyx Pharmaceuticals: Consultancy.

scholarly journals Untangling factors associated with country-specific COVID-19 incidence, mortality and case fatality rates during the first quarter of 2020

2020 ◽  
Author(s):  
Lev Shagam
Keyword(s):  
Case Fatality Rate ◽  
Case Fatality ◽  
Mortality Rates ◽  
Press Freedom ◽  
Gdp Per Capita ◽  
Model Case ◽  
Factors Associated ◽  
Incidence And Mortality ◽  
Per Capita ◽  
Country Specific

AbstractAt early stages of the COVID-19 pandemic which we are experiencing, the publicly reported incidence, mortality and case fatality rates (CFR) vary significantly between countries. Here we aim to untangle factors that are associated with the differences during the first quarter of the year 2020. Number of performed COVID-19 tests has a strong correlation with country-specific incidence (p < 2 × 10−16) and mortality rate (p = 5.1 × 10−8). Using multivariate linear regression we show that incidence and mortality rates correlate significantly with GDP per capita (p = 2.6 × 10−15 and 7.0 × 10−4, respectively), country-specific duration of the outbreak (2.6 × 10−4 and 0.0019), fraction of citizens over 65 years old (p = 0.0049 and 3.8 × 10−4) and level of press freedom (p = 0.021 and 0.019) which cumulatively explain 80% of variability of incidence and more than 60% of variability of mortality of the disease during the period analyzed. Country hemisphere demonstrated significant correlation only with mortality (p = 0.17 and 0.036) whereas population density (p = 0.94 and p = 0.75) and latitude (p = 0.61 and 0.059) did not reach significance in our model. Case fatality rate is shown to rise as the outbreak progresses (p=0.028). We rank countries by COVID-19 mortality corrected for incidence and the factors that were shown to affect it, and by CFR corrected for outbreak duration, yielding very similar results. Among the countries where the outbreak started after the 15th of February and with at least 1000 registered patients during the period analyzed, the lowest corrected CFR are seen in Israel, South Africa and Chile. The ranking results should be considered with caution as they do not consider all confounding factors or data reporting biases.

scholarly journals Racial disparities in COVID-19 mortality are driven by unequal infection risks.

2020 ◽  
Author(s):  
Jon Zelner ◽  
Rob Trangucci ◽  
Ramya Naraharisetti ◽  
Alex Cao ◽  
Ryan Malosh ◽  
...  
Keyword(s):  
Racial Disparities ◽  
Data Science ◽  
Age Groups ◽  
Case Fatality ◽  
The United States ◽  
Mortality Rates ◽  
Bayesian Regression ◽  
Mortality Data ◽  
Incidence And Mortality ◽  
The U.S

Background. As of August 5, 2020, there were more than 4.8M confirmed and probable cases and 159K deaths attributable to SARS-CoV-2 in the United States, with these numbers undoubtedly reflecting a significant underestimate of the true toll. Geographic, racial-ethnic, age and socioeconomic disparities in exposure and mortality are key features of the first and second wave of the U.S. COVID-19 epidemic. Methods. We used individual-level COVID-19 incidence and mortality data from the U.S. state of Michigan to estimate age-specific incidence and mortality rates by race/ethnic group. Data were analyzed using hierarchical Bayesian regression models, and model results were validated using posterior predictive checks. Findings. In crude and age-standardized analyses we found rates of incidence and mortality more than twice as high than Whites for all groups other than Native Americans. Of these, Blacks experienced the greatest burden of confirmed and probable COVID-19 infection (Age- standardized incidence = 1,644/100,000 population) and mortality (age-standardized mortality rate 251/100,000). These rates reflect large disparities, as Blacks experienced age-standardized incidence and mortality rates 5.6 (95% CI = 5.5, 5.7) and 6.9 (6.5, 7.3) times higher than Whites, respectively. We also found that the bulk of the disparity in mortality between Blacks and Whites is driven by dramatically higher rates of COVID-19 infection across all age groups, particularly among older adults, rather than age-specific variation in case-fatality rates. Interpretation. This work suggests that well-documented racial disparities in COVID-19 mortality in hard-hit settings, such as the U.S. state of Michigan, are driven primarily by variation in household, community and workplace exposure rather than case-fatality rates. Funding. This work was supported by a COVID-PODS grant from the Michigan Institute for Data Science (MIDAS) at the University of Michigan. The funding source had no role in the preparation of this manuscript.

scholarly journals Contemporary incidence and mortality rates of kidney cancer in the United States

2014 ◽  
Vol 8 (7-8) ◽  
pp. 247 ◽  
Author(s):  
Giorgio Gandaglia ◽  
Praful Ravi ◽  
Firas Abdollah ◽  
Abd-El-Rahman M. Abd-El-Barr ◽  
Andreas Becker ◽  
...  
Keyword(s):  
Kidney Cancer ◽  
The United States ◽  
Mortality Rates ◽  
Incidence Rates ◽  
Short Term ◽  
Annual Percent Change ◽  
Cancer Specific Survival ◽  
Incidence And Mortality ◽  
Short Term Mortality ◽  
Adjusted Incidence

Introduction: This is a timely update of incidence and mortality for renal cell carcinoma (RCC) in the United States.Methods: Relying on the Surveillance, Epidemiology, and End Results (SEER) database, we computed age-adjusted incidence, mortality rates and 5-year cancer-specific survival (CSS) for patients with histologically confirmed kidney cancer between 1975 and 2009. Long-term (1975–2009) and short-term (2000–2009) trends were examined by joinpoint analysis, and quantified using the annual percent change (APC). The reported findings were stratified according to disease stage.Results: Age-adjusted incidence rates of RCC increased by +2.76%/year between 1975 and 2009 (from 6.5 to 17.1/100 000 person years, p < 0.001), and by +2.85%/year between 2000 and 2009 (p < 0.001). For the same time points, the corresponding APC for the incidence of localized stage were +4.55%/year (from 3.0 to 12.2/100 000 person years, p < 0.001), and +4.42%/year (p < 0.001), respectively. The incidence rates of regional stage increased by +0.88%/year between 1975 and 2009 (p < 0.001), but stabilized in recent years (2000–2009: +0.56%/year, p = 0.4). Incidence rates of distant stage remained unchanged in long- and short-term trends. Overall mortality rates increased by +1.72%/year between 1975 and 2009 (from 1.2 to 5.0/100 000 person-years, P<0.001), but stabilized between 1994 and 2004 (p = 0.1). Short-term mortality rates increased in a significant fashion by +3.14%/year only for localized stage (p < 0.001).Interpretation: In contemporary years, there is a persisting upward trend in incidence and mortality of localized RCC.

scholarly journals Trends in peripheral arterial disease incidence and mortality in EU15+ countries 1990–2017

2020 ◽  
pp. 204748731989962 ◽  
Author(s):  
Richard Goodall ◽  
Justin D Salciccioli ◽  
Alun Huw Davies ◽  
Dominic Marshall ◽  
Joseph Shalhoub
Keyword(s):  
United States ◽  
Peripheral Arterial Disease ◽  
Medical Therapy ◽  
Disease Incidence ◽  
Arterial Disease ◽  
The United States ◽  
Mortality Rates ◽  
Incidence Rates ◽  
Incidence And Mortality ◽  
Peripheral Arterial

Aims The aim was to assess trends in peripheral arterial disease (PAD) incidence and mortality rates in European Union(15+) countries between 1990 and 2017. Methods and Results This observational study used data obtained from the 2017 Global Burden of Disease study. Age-standardised mortality and incidence rates from PAD were extracted from the Global Health Data Exchange for EU15+ countries for the years 1990–2017. Trends were analysed using Joinpoint regression analysis. Between 1990 and 2017, the incidence of PAD decreased in all 19 EU15+ countries for females, and in 18 of 19 countries for males. Increasing PAD incidence was observed only for males in the United States (+1.4%). In 2017, the highest incidence rates were observed in Denmark and the United States for males (213.6 and 202.3 per 100,000, respectively) and in the United States and Canada for females (194.8 and 171.1 per 100,000, respectively). There was a concomitant overall trend for increasing age-standardised mortality rates in all EU15+ countries for females, and in 16 of 19 EU15+ countries for males between 1990 and 2017. Italy (–25.1%), Portugal (–1.9%) and Sweden (–0.6%) were the only countries with reducing PAD mortality rates in males. The largest increases in mortality rates were observed in the United Kingdom (males +140.4%, females +158.0%) and the United States (males +125.7%, females +131.2%). Conclusions We identify shifting burden of PAD in EU15+ countries, with increasing mortality rates despite reducing incidence. Strong evidence supports goal-directed medical therapy in reducing PAD mortality – population-wide strategies to improve compliance to optimal goal-directed medical therapy are warranted.

scholarly journals Racial Disparities in Coronavirus Disease 2019 (COVID-19) Mortality Are Driven by Unequal Infection Risks

2020 ◽  
Author(s):  
Jon Zelner ◽  
Rob Trangucci ◽  
Ramya Naraharisetti ◽  
Alex Cao ◽  
Ryan Malosh ◽  
...  
Keyword(s):  
Native Americans ◽  
Racial Disparities ◽  
Age Groups ◽  
Case Fatality ◽  
Credible Interval ◽  
The United States ◽  
Mortality Rates ◽  
Bayesian Regression ◽  
Mortality Data ◽  
Incidence And Mortality

Abstract Background As of 1 November 2020, there have been &gt;230 000 deaths and 9 million confirmed and probable cases attributable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the United States. However, this overwhelming toll has not been distributed equally, with geographic, race/ethnic, age, and socioeconomic disparities in exposure and mortality defining features of the US coronavirus disease 2019 (COVID-19) epidemic. Methods We used individual-level COVID-19 incidence and mortality data from the state of Michigan to estimate age-specific incidence and mortality rates by race/ethnic group. Data were analyzed using hierarchical Bayesian regression models, and model results were validated using posterior predictive checks. Results In crude and age-standardized analyses we found rates of incidence and mortality more than twice as high than for Whites for all groups except Native Americans. Blacks experienced the greatest burden of confirmed and probable COVID-19 (age-standardized incidence, 1626/100 000 population) and mortality (age-standardized mortality rate, 244/100 000). These rates reflect large disparities, as Blacks experienced age-standardized incidence and mortality rates 5.5 (95% posterior credible interval [CrI], 5.4–5.6) and 6.7 (95% CrI, 6.4–7.1) times higher than Whites, respectively. We found that the bulk of the disparity in mortality between Blacks and Whites is driven by dramatically higher rates of COVID-19 infection across all age groups, particularly among older adults, rather than age-specific variation in case-fatality rates. Conclusions This work suggests that well-documented racial disparities in COVID-19 mortality in hard-hit settings, such as Michigan, are driven primarily by variation in household, community, and workplace exposure rather than case-fatality rates.

scholarly journals Hepatocellular Carcinoma Incidence, Mortality, and Survival Trends in the United States From 1975 to 2005

2009 ◽  
Vol 27 (9) ◽  
pp. 1485-1491 ◽  
Author(s):  
Sean F. Altekruse ◽  
Katherine A. McGlynn ◽  
Marsha E. Reichman
Keyword(s):  
United States ◽  
Hepatocellular Carcinoma ◽  
At Risk ◽  
Cancer Mortality ◽  
Survival Rates ◽  
The United States ◽  
Mortality Rates ◽  
Incidence Rates ◽  
Incidence And Mortality ◽  
Adjusted Incidence

Purpose Hepatocellular carcinoma (HCC) is the third leading cause of cancer mortality worldwide. Incidence rates are increasing in the United States. Monitoring incidence, survival, and mortality rates within at-risk populations can facilitate control efforts. Methods Age-adjusted incidence trends for HCC were examined in the Surveillance, Epidemiology, and End Results (SEER) registries from 1975 to 2005. Age-specific rates were examined for birth cohorts born between 1900 and 1959. Age-adjusted incidence and cause-specific survival rates from 1992 to 2005 were examined in the SEER 13 registries by race/ethnicity, stage, and treatment. United States liver cancer mortality rates were also examined. Results Age-adjusted HCC incidence rates tripled between 1975 and 2005. Incidence rates increased in each 10-year birth cohort from 1900 through the 1950s. Asians/Pacific Islanders had higher incidence and mortality rates than other racial/ethnic groups, but experienced a significant decrease in mortality rates over time. From 2000 to 2005, marked increases in incidence rates occurred among Hispanic, black, and white middle-aged men. Between 1992 and 2004, 2- to 4-year HCC survival rates doubled, as more patients were diagnosed with localized and regional HCC and prognosis improved, particularly for patients with reported treatment. Recent 1-year survival rates remained, however, less than 50%. Conclusion HCC incidence and mortality rates continue to increase, particularly among middle-aged black, Hispanic, and white men. Screening of at-risk groups and treatment of localized-stage tumors may contribute to increasing HCC survival rates in the United States. More progress is needed.

scholarly journals Urban Air Pollution May Enhance COVID-19 Case-Fatality and Mortality Rates in the United States

2020 ◽  
Vol 1 (3) ◽  
pp. 100047 ◽  
Author(s):  
Donghai Liang ◽  
Liuhua Shi ◽  
Jingxuan Zhao ◽  
Pengfei Liu ◽  
Jeremy A. Sarnat ◽  
...  
Keyword(s):  
United States ◽  
Air Pollution ◽  
Urban Air Pollution ◽  
Case Fatality ◽  
The United States ◽  
Mortality Rates ◽  
Urban Air

scholarly journals National and Subnational Trends of Incidence and Mortality of Female Genital Cancers in Iran; 1990–2016

2020 ◽  
Vol 23 (7) ◽  
pp. 434-444
Author(s):  
Sahar Eftekharzadeh ◽  
Narges Ebrahimi ◽  
Mehrnoosh Samaei ◽  
Farnam Mohebi ◽  
Bahram Mohajer ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Incidence Rate ◽  
Gynecological Cancer ◽  
Fold Increase ◽  
Mortality Rates ◽  
Incidence Rates ◽  
Gynecological Cancers ◽  
Corpus Uteri ◽  
National Mortality ◽  
Incidence And Mortality

Background: The present study aims to assess the incidence and mortality rates of gynecological cancers and their changes from 1990 to 2016 at national and subnational levels in Iran. Methods: Annual estimates of incidence and mortality for gynecological cancers from 1990 to 2016 at national and subnational levels were generated as part of a larger project entitled National and Subnational Burden of Diseases, Injuries, and Risk Factors (NASBOD). After the precise processing of data extracted from the Iran Cancer Registry, annual age-standardized incidence and mortality rates were calculated for each cancer, province, year and age group during the period of the study. Results: In 2016, gynecological cancers constituted 8.0% of new cancer cases among women of all ages compared to 3.7% of new cases of cancer among women in 1990. The incidence rate of gynecological cancers has increased from 2.5 (0.9-5.6) per 100000 women in 1990 to 12.3 (9.3–15.7) per 100000 women in 2016, and the most common gynecological cancer has changed from cervical cancer in 1990 to corpus uteri cancer in 2016. Age-standardized incidence rates of ovarian, corpus uteri and vulvovaginal cancers increased from 1.3 (0.5–2.4), 1.7 (0.6–3.0), and 0.3 (0.0–0.7) in 1990 to 4.4 (3.6–5.2), 9.9 (6.8–13.4), and 0.6 (0.2–1.0) in 2016, respectively, showing a 3.3, 5.8 and 1.7-fold increase during this period. Age-standardized incidence rate of cervical cancer was 2.4 (1.7–3.3) cases per 100000 women in 2016 and did not differ significantly from the beginning of the study. An overall reduction was seen in national mortality to incidence ratios (MIR) from 2000 to 2015. Conclusion: The incidence rates of all gynecological cancers in different provinces have shown a converging trend that could indicate that attempts toward health equality have been effective. The declining trend of MIR could be interpreted as advancements in detection of cancer in its early stages and also improvements in treatments, in turn reflecting improvements in access to and quality of care.

Sign in / Sign up

Export Citation Format

Share Document